Early diagnosis of tuberculosis and detection of drug-resistant TB is important for effective disease management. The prevalence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) is increasing worldwide, both among new and previously treated TB cases. Besides, there are estimated to be 1.7 billion people living with latent tuberculosis and a potential source of active tuberculosis in the future. In 2018, the World Health Organization (WHO) estimated burden of TB disease was 10 million people and India’s highest number of new TB cases accounted for 27 % of the global burden. Mycobacterium tuberculosis (MTB) typically affects the lungs and virtually all organs. Tuberculosis (TB) is an infectious and insidious disease, its leading cause of significant morbidity and mortality globally. Current Perceptionson Advanced Molecular Diagnostics for Drug-Resistant Mycobacterium tuberculosis. Ramasamy P, Sounderrajan V, Vijayakumar K. It shall be helpful for early regimen design and TB management before mutations emerge and therefore, we believe that the worldwide TB infection will be eliminated by the use of NGS.ĭrug Resistant TB Mycobacterium Tuberculosis Molecular Diagnosis Next Generation Sequencing TB Treatmentĭownload this article as: Copy the following to cite this article: NGS is an essential resource for the tuberculosis communityeither target, WGS, or NGS a rapid method that offers a complete spectrum of Mycobacterium tuberculosis resistance mutations, strain typing for transmission surveillance, unlike traditional molecular or phenotypic DST. Imaging approaches Chest X-rays, CT, MRI, nuclear medicine technique as PET/CT are non-specific, plays an important role in the diagnosis and assessment of TB, but PET/CT sometimes results in false-positive or negative due to benign lesions.Currently using the point of care molecular modalities, Gene Xpert MTB/RIF and line probe assays focused only on resistance-conferring mutations in specific target hotspot regions, but did not identify novel mutations, outside mutations and they may miss some locally prevalent rifampicin-conferring mutations, and not provided a large number of antibiotics/antibiotic groups that are used for DRTB treatment.Recently revolutionized high throughput next generation sequencing (NGS) technologies are offering new prospects for molecular diagnosis, for example, infectious disease pathogens like tuberculosis, influenza, and most recently SARS-CoV-2. Prompt diagnosis of tuberculosis and detection of drug-resistant TB within a clinically appropriate timeframe is important for the effective management of the disease. Globally, rising drug-resistant tuberculosis is a significant public health concern. We are heavily invested in the production of new technology and the collaborative efforts of our dedicated Research and Development team enables us to create and distribute high quality products, including our renowned gene-specific qPCR kits.Pushparaju Ramasamy, Vignesh Sounderrajan, Kevin Kumar Vijayakumar and Shakila Harshavardhan*ĭepartment of Molecular Microbiology, School of Biotechnology,Madurai Kamaraj University, Madurai, India, 625021 We pride ourselves on continuously developing and optimising our products, ensuring our customers are provided with high-quality data. We are a company with a large network of global customers- our combined product knowledge of over 20 years has allowed us to meet customer needs so we can maximise the level of satisfaction. Our product portfolio range includes PCR kits for infectious diseases, mutation assays and foodborne pathogens.Īdditionally, we provide consumables such as PCR plastic ware, filter tips, microbiology plastics and Real-Time qPCR instruments.
Advanced molecular diagnostics full#
We provide a full spectrum of solutions to meet specific molecular diagnostic requirements. Advanced Molecular Diagnostics is a global manufacturer of diagnostic devices, based in Nottingham, UK.
0 kommentar(er)
